Q1 Earnings Forecast for Neuronetics Issued By William Blair

Neuronetics, Inc. (NASDAQ:STIM - Free Report) - Equities researchers at William Blair upped their Q1 2025 earnings estimates for Neuronetics in a report issued on Wednesday, March 5th. William Blair analyst M. Andrew now forecasts that the company will post earnings per share of ($0.15) for the quarter, up from their prior forecast of ($0.25). The consensus estimate for Neuronetics' current full-year earnings is ($1.13) per share. William Blair also issued estimates for Neuronetics' Q2 2025 earnings at ($0.08) EPS, Q3 2025 earnings at ($0.10) EPS, Q4 2025 earnings at ($0.02) EPS, FY2025 earnings at ($0.35) EPS, Q1 2026 earnings at ($0.13) EPS, Q2 2026 earnings at ($0.08) EPS, Q3 2026 earnings at ($0.10) EPS, Q4 2026 earnings at ($0.02) EPS and FY2026 earnings at ($0.33) EPS.

Separately, Canaccord Genuity Group raised their target price on Neuronetics from $5.00 to $8.00 and gave the company a "buy" rating in a research note on Wednesday, March 5th.

Neuronetics Price Performance

NASDAQ STIM traded up $0.21 on Friday, reaching $4.54. 1,240,820 shares of the stock traded hands, compared to its average volume of 582,322. Neuronetics has a 12 month low of $0.52 and a 12 month high of $5.92. The company has a market cap of $137.78 million, a price-to-earnings ratio of -3.69 and a beta of 2.07. The firm's fifty day simple moving average is $3.26 and its 200 day simple moving average is $1.78. The company has a quick ratio of 2.87, a current ratio of 3.16 and a debt-to-equity ratio of 4.90.

Remove Ads

Hedge Funds Weigh In On Neuronetics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC lifted its stake in Neuronetics by 2.8% during the fourth quarter. Geode Capital Management LLC now owns 314,076 shares of the company's stock valued at $506,000 after buying an additional 8,466 shares in the last quarter. David J Yvars Group raised its holdings in shares of Neuronetics by 47.1% during the fourth quarter. David J Yvars Group now owns 46,325 shares of the company's stock valued at $75,000 after acquiring an additional 14,825 shares during the period. Tradewinds LLC. purchased a new stake in shares of Neuronetics in the 4th quarter valued at approximately $32,000. XTX Topco Ltd acquired a new position in Neuronetics in the 4th quarter worth approximately $49,000. Finally, GSA Capital Partners LLP grew its position in Neuronetics by 64.5% during the 3rd quarter. GSA Capital Partners LLP now owns 78,642 shares of the company's stock worth $60,000 after purchasing an additional 30,837 shares in the last quarter. Institutional investors and hedge funds own 53.59% of the company's stock.

Insider Activity at Neuronetics

In other Neuronetics news, CFO Stephen Furlong sold 17,307 shares of Neuronetics stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $4.11, for a total value of $71,131.77. Following the transaction, the chief financial officer now owns 454,420 shares in the company, valued at approximately $1,867,666.20. The trade was a 3.67 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Keith J. Sullivan sold 40,992 shares of the stock in a transaction on Monday, February 10th. The shares were sold at an average price of $3.28, for a total value of $134,453.76. Following the sale, the chief executive officer now owns 1,283,362 shares of the company's stock, valued at $4,209,427.36. This trade represents a 3.10 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 100,369 shares of company stock valued at $358,929 over the last ninety days. Insiders own 9.80% of the company's stock.

Neuronetics Company Profile

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.